Home › Blog › Weight Loss › Mounjaro Eligibility UK

Mounjaro Eligibility UK 2026: Complete Clinical Criteria, BMI Thresholds, Qualifying Conditions and How to Check if You Qualify Today

Overview: Mounjaro Eligibility in the UK

Mounjaro (tirzepatide) is a prescription-only medicine. It cannot be purchased over the counter or without a valid clinical assessment. Before any UK pharmacy — including Slinic — can dispense Mounjaro, a registered prescriber must assess whether you meet the clinical eligibility criteria and have no contraindications.

There are two sets of eligibility criteria to understand: private prescribing criteria (which Slinic uses) and NHS prescribing criteria (which are more restrictive and covered in our NHS Mounjaro guide). This guide covers both in full, but focuses primarily on private eligibility — which applies to the 2+ million UK adults currently accessing Mounjaro privately.

Private Mounjaro Eligibility: Slinic’s Clinical Criteria

Slinic’s prescribing criteria are aligned with the MHRA Summary of Product Characteristics for Mounjaro, the GPhC guidance for online weight loss prescribing (updated February 2025), and the clinical evidence base. They are not arbitrary commercial thresholds — they reflect the licensed indications and the clinical evidence for which patient populations benefit from and can safely receive tirzepatide.

BMI Thresholds Explained: 30, 27, and Why They Differ

The MHRA-approved Summary of Product Characteristics for Mounjaro specifies two distinct eligibility thresholds based on BMI:

BMI 30 or above — obesity threshold

Adults with a BMI of 30 or above are classified as obese by the World Health Organisation and NHS definitions. The clinical evidence for Mounjaro — principally from SURMOUNT-1 — was conducted in a population with a mean baseline BMI of approximately 38 kg/m². The MHRA licensed Mounjaro for adults with a BMI of 30 or above as the primary indication for weight management.

BMI 27 or above with qualifying condition — overweight threshold

Adults with a BMI of 27–29.9 are classified as overweight. NICE TA1026 and the MHRA licence both recognise that overweight patients with at least one weight-related health condition face elevated clinical risk and may benefit from Mounjaro treatment even at lower BMI values. The presence of a qualifying condition — such as type 2 diabetes, hypertension, or cardiovascular disease — elevates the risk-benefit ratio to a point where Mounjaro prescribing is clinically appropriate at BMI 27+.

How to calculate your BMI

BMI = weight (kg) ÷ height (m)²

Qualifying Conditions: The Complete List

For patients with BMI 27–29.9 (and for some ethnic groups, lower — see below), at least one of the following qualifying conditions is required for private Mounjaro eligibility at Slinic. These are the conditions for which weight reduction through Mounjaro is clinically indicated as a treatment adjunct:

Ethnic Group BMI Adjustments: Lower Thresholds That Apply

The NICE eligibility framework and Slinic’s clinical criteria both apply lower BMI thresholds for specific ethnic groups. This reflects the strong evidence that adults of South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean backgrounds experience obesity-related health risks at lower BMI values than white European populations.

Who Cannot Take Mounjaro: Absolute and Relative Contraindications

Absolute contraindications — Mounjaro is not appropriate

Relative contraindications — individual clinical assessment required

Drug Interactions: What Medications May Affect Eligibility

Mounjaro has a small number of clinically relevant drug interactions. These do not always make prescribing inappropriate but require assessment and in some cases monitoring or dose adjustment.

NHS Mounjaro Eligibility Criteria (2026)

For comparison, here are the current NHS eligibility criteria — significantly more restrictive than private criteria. Full detail in our Mounjaro NHS guide.

NHS vs Private Eligibility: Side by Side

Age Eligibility

Mounjaro is licensed for adults aged 18 and over in the UK. There is no upper age limit — older adults with obesity can and do benefit from treatment, though the complexity of medication management may increase with age due to polypharmacy and age-related changes in metabolism.

Under 18

Mounjaro is not currently licensed for patients under 18 in the UK. The TRIUMPH-3 trial is evaluating tirzepatide in adolescents aged 12–17 with obesity — results are expected in 2026–2027. Slinic does not prescribe Mounjaro for patients under 18. For adolescent obesity management, appropriate pathways include NHS tier 3 paediatric services.

Older adults (65+)

No upper age limit applies to Mounjaro eligibility. Older patients with obesity frequently have multiple qualifying conditions and may see particular benefit. Clinical considerations for older patients include greater complexity of existing medications, higher likelihood of relevant comorbidities, and the importance of lean muscle preservation during weight loss. Monthly clinical check-ins at Slinic specifically address these factors for older patients.

Pregnancy, Contraception and Family Planning

Mounjaro must not be used during pregnancy. It must be stopped before conception. Here is the complete guidance:

• Stop Mounjaro at least 4 weeks before planned conception — some guidance recommends stopping 2 months before to ensure full clearance
• Mounjaro may reduce the effectiveness of the combined oral contraceptive pill — use barrier contraception for 4 weeks after starting and after each dose increase (MHRA guidance, January 2025)
• If you become pregnant while taking Mounjaro, stop immediately and contact your GP or Slinic clinical team
• Do not use Mounjaro while breastfeeding — it is not known whether tirzepatide passes into breast milk

Improved fertility is a known effect of weight loss on conditions like PCOS. Patients who were not using contraception because they believed they could not conceive should consider their contraceptive needs when starting Mounjaro. See our complete Mounjaro and contraception guide for full clinical detail.

Previous Weight Loss Treatment and Eligibility

Your history of previous weight loss treatment does not disqualify you from Mounjaro. In fact, a history of previous attempts is one of the most common presentations at Slinic. Here is how different previous treatment histories affect your assessment:

10 Real Eligibility Scenarios

Rather than abstract criteria, here are ten realistic patient scenarios and the eligibility outcome for each.

What the Slinic Assessment Involves

Every Slinic patient goes through a clinical assessment before receiving a Mounjaro prescription. Here is exactly what it covers and why each element matters.

1. Personal and contact details

Name, date of birth, UK address — used for identity verification and medication dispatch.

2. Independent weight and height verification

Required under GPhC February 2025 guidance. You will be asked to provide evidence of your current weight — typically a photograph of your scales showing your weight. This ensures prescribing decisions are based on verified measurements, not self-reported estimates. Any provider not asking for this is not meeting current regulatory standards.

3. Medical history

Your prescriber reviews your qualifying conditions, any contraindications, and other relevant medical history including thyroid conditions, pancreatitis history, gastrointestinal disease, kidney function, and liver health.

4. Current medications

Full medication review for interactions — particularly oral contraceptives, levothyroxine, insulin, sulphonylureas, and warfarin as noted above.

5. Prescriber review

A registered Slinic prescriber reviews your complete assessment. This is not an algorithm — it is a qualified pharmacist prescriber or nurse prescriber making a clinical judgment. If they have questions, they contact you before approving or declining.

6. Approval and dispatch

If approved, your Mounjaro 2.5mg starting pen is dispatched within 24 hours via cold-chain tracked delivery.

Borderline Eligibility: Common Scenarios Explained

Some of the most common questions Slinic receives are from patients who are unsure whether they fall on the right side of the eligibility line. Here are the most frequently encountered borderline scenarios.

“My BMI is 29.8 — am I eligible?”

At BMI 29.8 without a qualifying condition, you do not currently meet Slinic’s prescribing threshold for Mounjaro (BMI 30+ without condition, or 27+ with condition). However, BMI calculations based on weight and height can have small measurement variations — if you have home scales and have not recently had your weight and height professionally measured, it is worth getting an accurate measurement. If you have even one qualifying health condition (type 2 diabetes, hypertension, high cholesterol, cardiovascular disease, sleep apnoea, NAFLD, PCOS, or obesity-related osteoarthritis), you would qualify at BMI 27+. Complete our assessment and let our prescriber make the clinical determination — they may also consider whether Wegovy is appropriate at a slightly lower BMI threshold.

“I have pre-diabetes — does that count as a qualifying condition?”

Yes. Pre-diabetes (impaired fasting glucose or impaired glucose tolerance) qualifies as a qualifying condition for Mounjaro eligibility at BMI 27+ at Slinic. The clinical rationale is identical to type 2 diabetes — Mounjaro’s dual mechanism improves insulin sensitivity and can reverse pre-diabetic states. Disclose your pre-diabetes diagnosis, your most recent HbA1c or fasting glucose reading, and any relevant test results in your assessment.

“I’m on blood pressure medication but I’ve never been formally diagnosed with hypertension”

Being prescribed antihypertensive medication is clinically equivalent to a hypertension diagnosis for eligibility purposes — you would not be on blood pressure medication without an elevated blood pressure diagnosis. List your antihypertensive medication in your assessment; our prescriber will note this as a qualifying condition.

“My BMI is 32 and I have anxiety and depression — are these qualifying conditions?”

Anxiety and depression are not on the current list of qualifying conditions for Mounjaro at BMI 27+. However, at BMI 32, you already meet the BMI 30+ threshold and do not need any qualifying condition. You are eligible for Mounjaro at Slinic on BMI alone.

“I had gallstones removed 2 years ago — can I take Mounjaro?”

A previous history of gallstones is not an absolute contraindication to Mounjaro. GLP-1 medications including Mounjaro are associated with a slightly increased risk of gallbladder events, particularly during rapid weight loss — and this is noted in the MHRA-approved Summary of Product Characteristics. If you have had your gallbladder removed (cholecystectomy), this is not a contraindication. If you have a history of gallstones with an intact gallbladder, this requires discussion at your assessment — our prescriber will consider your specific history and may recommend monitoring.

“I have a BMI of 31 and take sertraline — does this affect my eligibility?”

Sertraline and most other SSRIs do not have a clinically significant pharmacokinetic interaction with Mounjaro. At BMI 31, you meet the BMI 30+ threshold independently. Disclose your medications in the assessment — our prescriber will check for any specific interactions — but SSRI use is generally compatible with Mounjaro prescribing.

Maintaining Eligibility During Treatment

An important question that patients sometimes ask is whether they need to remain above the eligibility BMI threshold throughout treatment. The answer is clinically nuanced.

What happens if you lose weight below the threshold?

If you started Mounjaro at BMI 31 and successfully lose weight to BMI 28 during treatment — you have achieved the clinical goal. The prescribing decision at that point is not about re-applying the eligibility criteria as if you are a new patient. It is about whether continuing treatment is clinically appropriate to:

• Continue losing weight towards your target (if not yet reached)
• Maintain the weight lost (if at or near your target)
• Prevent the rebound weight gain documented in extension trial data

Clinical continuation decisions are made at your monthly Slinic check-in based on your progress, your target, and your clinical circumstances. Successfully losing weight on Mounjaro does not mean you must stop it — long-term maintenance prescribing is an increasingly accepted clinical model for obesity management.

Qualifying Conditions Deep Dive

Hypertension: what counts?

High blood pressure (hypertension) is defined as a sustained reading of 140/90 mmHg or above. A single elevated reading does not constitute hypertension — it requires either a sustained pattern over multiple readings or active treatment with antihypertensive medication. Evidence needed at assessment: formal diagnosis in your medical history, or current antihypertensive medication (amlodipine, ramipril, lisinopril, losartan, bendroflumethiazide, bisoprolol, or any other antihypertensive).

Type 2 diabetes: what counts?

A formal diagnosis of type 2 diabetes from your GP or diabetes team. Evidence: diagnosis in medical records, current diabetes medication (metformin, SGLT-2 inhibitors, DPP-4 inhibitors, insulin, sulphonylureas), or recent HbA1c of 48 mmol/mol (6.5%) or above. Pre-diabetes (HbA1c 42–47 mmol/mol) also qualifies as a condition at Slinic.

Cardiovascular disease: what counts?

Established cardiovascular disease — not cardiovascular risk. This means a documented history of: heart attack (myocardial infarction), angina (stable or unstable), stroke, TIA, peripheral arterial disease, heart failure, or significant coronary artery disease on investigation. Having cardiovascular risk factors (smoking, high cholesterol, family history) does not constitute cardiovascular disease as a qualifying condition — though it may affect the overall clinical assessment.

High cholesterol (dyslipidaemia): what counts?

A formal diagnosis of dyslipidaemia or high cholesterol, or current lipid-lowering medication (statins: atorvastatin, simvastatin, rosuvastatin; or other lipid-lowering agents: ezetimibe, fibrates, PCSK9 inhibitors). Evidence: diagnosis in medical history or current statin/lipid medication.

Obstructive sleep apnoea: what counts?

Formal diagnosis of obstructive sleep apnoea — typically requiring either an overnight sleep study (polysomnography or home sleep monitoring) or a diagnosis from a respiratory or sleep medicine physician. Use of a CPAP (continuous positive airway pressure) machine is strong evidence of diagnosed sleep apnoea. Self-reported snoring or suspected sleep apnoea without formal diagnosis does not independently qualify.

PCOS: what counts?

Formal diagnosis of polycystic ovary syndrome from a GP or gynaecologist, typically based on the Rotterdam criteria (two of three: irregular periods, hyperandrogenism, polycystic ovaries on ultrasound). Self-diagnosed PCOS without clinical confirmation is not sufficient at assessment — but diagnosis can be informal (i.e. GP-level diagnosis, not necessarily specialist-confirmed).

Mounjaro Eligibility with Specific Medication Classes

Patients on specific medication classes frequently ask whether these affect their eligibility. Here is a clear framework:

Not Eligible for Mounjaro? Here Are Your Alternatives

If you do not currently meet Mounjaro eligibility criteria, there are clinical alternatives worth considering.

Wegovy (semaglutide) — similar criteria, lower price

Wegovy has the same eligibility criteria as Mounjaro at Slinic (BMI 30+ or 27+ with qualifying condition) and starts from £99.99/pen — meaningfully cheaper than Mounjaro’s £139 starting price. If your BMI or conditions make Mounjaro ineligible in a specific edge case, Wegovy may not be either. But for patients who meet criteria and want to start with the lower-cost option, Wegovy is an excellent alternative. See our Wegovy page.

Wegovy pill — coming soon

The MHRA-approved Wegovy pill (oral semaglutide) will carry the same eligibility criteria as injectable Wegovy when it launches at Slinic. For needle-phobic patients who meet the criteria, this will be an option within weeks.

Lifestyle intervention while building towards eligibility

For patients with BMI 27-29.9 and no qualifying conditions, structured lifestyle intervention — reducing BMI further or developing conditions that increase clinical risk — may eventually bring them into eligibility range. This is not ideal clinical advice, but it is the honest picture of where the prescribing threshold sits.

Quick BMI Reference: Where Do You Stand?

Use this table to quickly identify your eligibility threshold based on your height. Find your height row, then check whether your current weight falls above the relevant BMI threshold.

For South Asian, Chinese, Middle Eastern, Black African and Caribbean backgrounds, the private eligibility threshold with a qualifying condition is BMI 23+ (approximately 53–68 kg depending on height, with one condition). Complete the Slinic assessment for your personalised determination.

Frequently Asked Questions

How to Maximise Your Chances of Qualifying

If you are borderline — close to the BMI threshold or uncertain about qualifying conditions — here is a practical guide to ensuring your assessment gives you the best chance of an accurate eligibility determination.

Get an accurate weight measurement

Home scales vary in accuracy. Weigh yourself first thing in the morning, after using the bathroom, and without clothing for the most accurate reading. If your home scales have not been recently calibrated, consider using pharmacy or GP surgery scales. A difference of 1–2 kg can be the difference between BMI 29 and BMI 30. BMI also depends on your height — measure your height accurately without shoes.

List every qualifying condition — including ones managed with medication

Patients sometimes forget conditions they have had for years and manage routinely with medication. Go through your current medication list — every medication you take for a long-term condition is evidence of that condition. Atorvastatin = high cholesterol = qualifying condition. Ramipril or lisinopril = hypertension = qualifying condition. Metformin = type 2 diabetes = qualifying condition. CPAP machine = sleep apnoea = qualifying condition. Statins, antihypertensives, and diabetes medications all represent qualifying conditions even if you feel well-controlled.

Declare your ethnic background for adjusted thresholds

If you are of South Asian, Chinese, Middle Eastern, or Black African/Caribbean background, lower BMI thresholds apply. A BMI of 26 with type 2 diabetes qualifies you for Mounjaro at Slinic under the adjusted thresholds — but only if you declare your ethnic background in your assessment. Our prescribers apply the correct adjusted criteria automatically once they know. Many patients from eligible ethnic backgrounds complete assessments without mentioning this and are declined when they would have been approved under adjusted criteria.

Be honest about contraindications

The eligibility assessment is a clinical safety screening process, not a hurdle. Disclosing accurate medical history — including contraindications like MTC family history or pregnancy — protects you. If you are prescribed Mounjaro inappropriately because a contraindication was not disclosed, the clinical risk is yours to bear. Slinic’s prescribers make sensible, proportionate clinical judgments about borderline situations — they are not looking for reasons to decline; they are looking to prescribe safely.

If you are not eligible now, ask what would change that

If your assessment results in a decline, your Slinic prescriber will explain why and in most cases can tell you what circumstances would change the eligibility determination — whether that is a slightly higher BMI, an additional qualifying condition being documented by your GP, or a change in circumstances. In some cases the answer is simply to wait until NHS eligibility expands further, at which point private criteria may also evolve.

References

1. Electronic Medicines Compendium. Mounjaro KwikPen Summary of Product Characteristics. 2026.
2. NICE TA1026 — Tirzepatide for managing overweight and obesity. 2025.
3. GPhC. Guidance for registered pharmacies providing services at a distance. Updated February 2025. pharmacyregulation.org
4. MHRA Drug Safety Update. Tirzepatide — January 2025. gov.uk
5. WHO. Appropriate body-mass index for Asian populations. Lancet 2004;363(9403):157-163.
6. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022.

Related Guides